DLBS1033 treatment for ischemic stroke patients and clinical outcomes: systematic review of randomized controlled trial study

Abstract

DLBS1033 is a lumbrokinase earned from extraction of earthworms, Lumbricus rubellus. Lumbrokinase has 2 main activities: fibrinolytic and fibrinogenolytic – these activities reduce blood viscosity and platelet aggregation. With all of those properties, DLBS1033 will be a promising agent in patients with ischemic stroke. The objective of this research is to identify the advantage of DLBS1033 in ischemic stroke patients’ clinical outcome. We used Pub Med, Cochrane, and Clinical Key as our major database for this systematic review. ”DLBS1033”, ”lumbrokinase”, and ”stroke” keywords selected to particularize the search. The 2 authors calculated each of the studies using Jadad score. Only certain studies with scores above 3 will be included for further review using PRISMA checklist. There were 27 studies relating to DLBS1033 or lumbrokinase and stroke. Further examination by 2 authors resulted in 23 articles being removed leaving 2 studies. Subjects in all of the said studies are ischemic stroke patients; predominantly male patients. All of the said studies compare DLBS1033 with standard therapy; either utilizing DLBS1033 as an additional therapy or as a separate therapy. Clinical outcomes were measured using NIHSS and BI. Compared to standard therapy, DLBS1033 proved successful in improving clinical outcomes among patients with ischemic stroke. It’s also found to be safe with none serious adverse events and significantly has lower bleeding events.